StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Veracyte's operating cash flow for the twelve months ending Jun 30, 2026 was $178.38M, up 90.9% year over year. For fiscal 2025 it was $136.31M, up 81.5% from the year before. The highest annual figure on record is $136.31M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$136.31M+81.5%
FY2024Dec 31, 2024$75.10M+69.8%
FY2023Dec 31, 2023$44.22M+486.9%
FY2022Dec 31, 2022$7.54M–
FY2021Dec 31, 2021-$31.62M–
FY2020Dec 31, 2020-$9.71M–
FY2019Dec 31, 2019-$3.23M–
FY2018Dec 31, 2018-$13.52M–
FY2017Dec 31, 2017-$23.92M–
FY2016Dec 31, 2016-$27.98M–
FY2015Dec 31, 2015-$26.97M–
FY2014Dec 31, 2014-$27.63M–
FY2013Dec 31, 2013-$19.16M–
FY2012Dec 31, 2012-$7.17M–
FY2011Dec 31, 2011-$13.52M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$45.83M+36.4%
Q1 FY2026Mar 31, 2026$35.22M+556.8%
Q4 FY2025Dec 31, 2025$52.58M+114.4%
Q3 FY2025Sep 30, 2025$44.76M+49.4%
Q2 FY2025Jun 30, 2025$33.61M+13.6%
Q1 FY2025Mar 31, 2025$5.36M–
Q4 FY2024Dec 31, 2024$24.52M+57.7%
Q3 FY2024Sep 30, 2024$29.96M+111.4%
Q2 FY2024Jun 30, 2024$29.58M+77.4%
Q1 FY2024Mar 31, 2024-$8.97M–
Q4 FY2023Dec 31, 2023$15.55M+59.6%
Q3 FY2023Sep 30, 2023$14.17M+101.7%
Q2 FY2023Jun 30, 2023$16.67M–
Q1 FY2023Mar 31, 2023-$2.17M–
Q4 FY2022Dec 31, 2022$9.74M+15.4%
Q3 FY2022Sep 30, 2022$7.03M–
Q2 FY2022Jun 30, 2022-$363.00K-119.2%
Q1 FY2022Mar 31, 2022-$8.87M–
Q4 FY2021Dec 31, 2021$8.45M+273.6%
Q3 FY2021Sep 30, 2021-$1.39M-179.5%
Q2 FY2021Jun 30, 2021$1.89M–
Q1 FY2021Mar 31, 2021-$40.56M–
Q4 FY2020Dec 31, 2020$2.26M+26.3%
Q3 FY2020Sep 30, 2020$1.75M–
Q2 FY2020Jun 30, 2020-$8.42M–
Q1 FY2020Mar 31, 2020-$5.30M–
Q4 FY2019Dec 31, 2019$1.79M–
Q3 FY2019Sep 30, 2019-$1.56M–
Q2 FY2019Jun 30, 2019-$2.46M–
Q1 FY2019Mar 31, 2019-$1.01M–
Q4 FY2018Dec 31, 2018-$1.23M–
Q3 FY2018Sep 30, 2018-$1.78M–
Q2 FY2018Jun 30, 2018-$3.10M–
Q1 FY2018Mar 31, 2018-$7.41M–
Q4 FY2017Dec 31, 2017-$5.82M–
Q3 FY2017Sep 30, 2017-$5.10M–
Q2 FY2017Jun 30, 2017-$4.91M–
Q1 FY2017Mar 31, 2017-$8.09M–
Q4 FY2016Dec 31, 2016-$4.23M–
Q3 FY2016Sep 30, 2016-$7.44M–

More Veracyte figures

See a number that looks wrong?